Fig. 9: Schematic diagram illustrating the proposed mechanism from the study. | npj Precision Oncology

Fig. 9: Schematic diagram illustrating the proposed mechanism from the study.

From: ZEB1 and ALKBH5 coregulate CRABP2 and FABP5 and jointly determine the sensitivity of anaplastic thyroid cancers to gemcitabine and retinoic acid

Fig. 9: Schematic diagram illustrating the proposed mechanism from the study.

In a subset of ATC cells (including THJ-11T, THJ-16T, and THJ-21T cells), following combined treatment with GEM and RA, the ZEB1/EP300/KAT2B transcriptional complex relocates from the FABP5 promoter to the CRABP2 promoter, thereby increasing CRABP2 transcription. Concurrently, the binding of METTL3 and ALKBH5 shifts from CRABP2 mRNA to FABP5 mRNA, facilitating the degradation of FABP5. Collectively, these changes result in the upregulation of CRABP2 and the downregulation of FABP5, increasing the sensitivity of ATC cells to GEM and RA treatment.

Back to article page